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Aims: Ischaemic cardiomyopathy (ICM) leads to impaired contraction and ventricular 
dysfunction causing high rates of morbidity and mortality. Epigenomics allows the 
identification of epigenetic signatures in human diseases. We analyse the differential 
epigenetic patterns of ASB gene family in ICM patients and relate these alterations to 
their haemodynamic and functional status.  
Methods and Results: Epigenomic analysis was carried out using 16 left ventricular 
(LV) tissue samples, 8 from ICM patients undergoing heart transplantation and 8 from 
control (CNT) subjects without cardiac disease. We increased the sample size up to 13 
ICM and 10 CNT for RNA-sequencing and to 14 ICM for pyrosequencing analyses. We 
found a hypermethylated profile (cg11189868) in the ASB1 gene that showed a 
differential methylation of 0.26Δβ, P < 0.05. This result was validated by 
pyrosequencing technique (0.23Δβ, P < 0.05). Notably, the methylation pattern was 
strongly related to LV ejection fraction (r = -0.849, P = 0.008) stroke volume (r = -
0.929, P = 0.001) and end-systolic and diastolic LV diameters (r = -0.743, P = 0.035 for 
both). ASB1 showed a down regulation in mRNA levels (-1.2 fold, P < 0.05). 
Conclusion: Our findings link a specific ASB1 methylation pattern to LV structure and 
performance in end-stage ICM, opening new therapeutic opportunities and providing 
new insights regarding which is the functionally relevant genome in the ischemic failing 
myocardium. 
Keywords: ischaemic cardiomyopathy; epigenomics; heart failure; left ventricular dysfunction; 
stroke volume; ASB1. 
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INTRODUCTION 
There are several large-scale studies deciphering the alterations in human heart failure 
(HF) proteome and genome, to elucidate the molecular mechanisms involved in the 
pathophysiology of this syndrome.
1, 2
 However, apart from these global changes, there 
are other omic approaches revealing insights in the regulation of expression patterns in 
disease. Epigenomics has allowed the identification of epigenetic signatures in human 
diseases including different types of cancer,
3-5
 neurological disorders
6, 7
 or infections.
8
 
There are also some evidences of their role in cardiovascular diseases.
9-11
 Moreover, the 
development of the novel approach MethylationEPIC BeadChip (Infinium) microarray, 
has improved greatly the coverage, reaching 850,000 CpG methylation sites (850K).
12
 
Our group has extensively studied different pathophysiological factors in HF, including 
apoptosis processes
13
 and cytoskeletal and cell adhesion molecular alterations
14, 15
 that 
are important to clinical status of patients. Interestingly, the gene family ASB codifies 
Ankyrin repeat and SOCS box proteins that mediate, through their specific domains, 
protein-protein interactions, protein synthesis, and myogenesis and proteasomal 
degradation processes.
16-18
 Moreover members of this family have been related to 
skeletal muscle mass regulation.
19
 
Taking into account these previous data and the increasing evidence of the influence of 
epigenetic changes in the pathophysiology of human diseases, we hypothesize that the 
epigenetic changes in the ASB gene family may relate to the ischaemic left ventricular 
(LV) performance. We analysed specific gene methylation changes in patients with end 
stage ischaemic cardiomyopathy (ICM) compared with those in control (CNT) subjects. 
Furthermore, we related these alterations with LV function and with invasively 
calculated stroke volume (SV). 
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METHODS 
Cardiac tissue samples 
Epigenomic experiments were conducted with 8 LV tissue samples from ICM patients 
undergoing cardiac transplantation and 8 non-diseased donor hearts (CNT), increasing 
the sample size for RNA-sequencing (13 ICM) and pyrosequencing (14 ICM). Clinical 
history, hemodynamic study, ECG, and Doppler echocardiography data were available. 
These data were collected by physicians blind to the subsequent analysis of LV function 
that was carried out. Patients were functionally classified according to the NYHA 
criteria and were receiving medical treatment following the guidelines of the European 
Society of Cardiology.
20
 
All CNTs had normal LV function (LVEF>50%) and none had any history of cardiac 
disease. Samples were obtained from non-diseased donor hearts that had been rejected 
for cardiac transplantation owing to size or blood type incompatibility. Donors died of 
either cerebrovascular or motor vehicle accidents.  
Tissue samples were collected from near the apex of left ventricle, maintained in 0.9% 
NaCl, and preserved at 4 °C for a maximum of 4.4±3 h after the coronary circulation 
loss. Then, were stored at −80°C until used. Appropriate handling and rapid sample 
collection and storage, by our on call (24 h) team over the last 10 years, led to the 
obtaining of high quality samples (RIN≥9 and DNA ratios 260/280 ~1.8 and 260/230 
~2.0). 
This study was approved by the Ethics Committee (Biomedical Investigation Ethics 
Committee of La Fe University Hospital of Valencia, Spain), and was conducted in 
accordance with the guidelines of the Declaration of Helsinki.
21
 Signed informed 
consent was obtained from each patient. 
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DNA extraction, quality assessment and Infinium MethylationEPIC BeadChip 
DNA was extracted using a modified phenol-chloroform protocol. The epigenomic 
study (Infinium MethylationEPIC BeadChip platform (Illumina) used the 
HumanMethylation450 BeadChip protocol. Methylation level was displayed as beta 
values ranging from 0–1. Beta-values with detection P>0.01 were removed from the 
analysis. The raw data were normalized and background corrected. The resulting raw 
data (IDATs) were normalized and background corrected using the methylation module 
(1.9.0) in GenomeStudio (v2011.1) software. 
Validation by pyrosequencing 
500ng of DNA were converted using the EZ DNA Methylation Gold (Zymo Research) 
bisulfite conversion kit, following the manufacturer’s recommendations. Specific sets of 
primers for PCR amplification and sequencing were designed (PyroMark assay design 
v2.0.01.15) to hybridize with CpG-free sites ensuring methylation-independent 
amplification. PCR was performed with biotinylated primers and the PyroMark Vacuum 
Prep Tool (Biotage, Sweden) was used to prepare single-stranded PCR products. 
Reactions were performed in a PyroMark Q24 System version 2.0.6 (Qiagen) and the 
methylation value was obtained from the average of the CpG dinucleotides included in 
the sequence analysed.  
RNA-sequencing and computational analysis 
These protocols were performed as described in.
14
 The data presented in this manuscript 
have been deposited in NCBI’s Gene Expression Omnibus (GEO)22 (GSE55296) 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55296). 
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Statistical methods 
Data were analysed as previously described.
14
 P<0.05 was considered statistically 
significant. CpGs with Δβ≥±0.1 were considered differentially methylated.  
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RESULTS  
Clinical characteristics of patients 
For epigenomic studies we analyzed 8 ICM samples, patients were all men with a mean 
age of 53±5 years, and 8 CNT samples, 63% men with a mean age of 59±20 years. 
Sample size was increased for RNA-sequencing (13 ICM), all men with a mean age of 
54±7 years and 10 CNT, 80% men with a mean age of 47±16 years. And also for 
pyrosequencing (14 ICM), all men with a mean age of 53±6 years. Patients had a 
NYHA classification of III-IV and were diagnosed with comorbidities including 
hypertension and diabetes mellitus. Comorbidities and other echocardiographic data 
were not available for the CNT group, in accordance with the Spanish Organic Law on 
Data Protection 15/1999. Clinical characteristics of patients are shown in Table 1. 
Methylation profile of ASB family and gene expression analysis of ASB1 gene 
We analyzed the methylation status (β-values) of CpGs belonging to the ASB gene 
family between 8 ICM patients and 8 CNT donors using the 850K methylation array. 
Analysis of CpG differential methylation revealed the presence of only one 
hypermethylated CpG site of all ASB family, located in the ASB1 gene 
(chr2:239344401-239344627) with a Δβ>0.1. The hypermethylated CpG site 
(cg11189868), displayed a differential methylation profile of 0.26Δβ, P<0.05 (Figure 
1A). We also validated these results through pyrosequencing, observing a 0.23Δβ, 
P<0.05 (Figure 1B). 
Further, we performed an analysis of ASB1 mRNA levels through RNA-sequencing and 
we found a downregulation of ASB1 gene expression of -1.2 fold, P<0.05 (Figure 1C). 
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Relationships between ASB1 differential methylation and LV function and 
performance 
We sought to investigate the potential relationships between ASB1 differential 
methylations and expression and hemodynamic and echocardiographic parameters of 
ICM patients. Interestingly, the differential methylation pattern of ASB1 cg11189868 
was strongly linked to SV (r = -0.929, P = 0.001) and LVEF (r = -0.849, P = 0.008) 
(Figure 2). This ASB1 methylation profile also related to end-systolic and end-diastolic 
LV diameters (r = -0.743, P = 0.035 for both). 
8 
 
DISCUSSION 
In this study, we analyse the methylation profile of ASB gene family in ICM patients, 
showing the presence of a differentially methylated CpG site located at the ASB1 gene. 
None of the other ASB family genes showed methylation changes. This analysis 
demonstrates the presence, not previously reported, of a strong association between a 
differentially methylated pattern, validated by pyrosequencing, of ASB1 gene in ICM 
subjects with the hemodynamic status, LV performance and cardiac function of these 
patients. 
In previous studies, we have analysed the transcriptomic changes in cytoskeletal 
components of HF patients,
15
 showing important alterations and links with LV 
dysfunction. Importantly, the gene coding of ankyrin repeat domain 1, ANKRD1, 
showed relationships with functional status of these patients, indicating a relevant role 
of this ankyrin gene in HF.  
ASB gene family codify Ankyrin repeat and SOCS box proteins, being involved in 
protein-protein interactions acting as adaptors that target proteins for proteasomal 
degradation.
18
 Scant data are available about the specific function of ASB1, relating it 
with alterations in spermatogenesis,
23
 moreover, no studies have been conducted in 
cardiac tissues, but its protein superfamily has relevant implications in controlling the 
skeletal muscle contractile apparatus structural fixation and adequate regulation of 
differentiation steps.
17
 ASB2 has been implicated as a negative regulator of skeletal 
muscle mass through the TGF-β pathway, indicating that increased levels prevents 
hypertrophy.
19
 Our results and the structural domain similarity in this gene family 
suggest a similar function for ASB1 in the heart muscle. As demonstrated, gain of 
methylation of ASB1 CpG island closely relates to LV function, dimensions, and output, 
and none of the other 18 ASB family genes show such change, indicating that an 
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increased degree of methylation may be an indicator of deteriorating hemodynamic and 
cardiac function. In contrast, the ASB1 gene expression calculated by means of the 
RNA-sequencing technique does not showed any LV significant relationships, 
suggesting a prominent role for this DNA methylation, maybe related to an unknown 
specific function in coding. 
Conclusions 
Our findings strongly link a specific ASB1 methylation pattern to LV morphology and 
performance in end stage ICM, and provide new insight and raising questions regarding 
which is the functionally relevant genome for the ischaemic failing myocardium. 
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Table 1. Clinical characteristics of ischaemic cardiomyopathy patients. 
ICM, ischaemic cardiomyopathy; NYHA, New York Heart Association; BMI, body 
mass index; LVEF, ejection fraction; LVESD, left ventricular end-systolic diameter; 
LVEDD, left ventricular end-diastolic diameter. 
 
 
 
 
 
 
 ICM (n=8) ICM (n=13) ICM (n=14) 
 Epigenomics RNA sequencing Pyrosequencing 
Age (years) 53±5 54±7 53±6 
Gender male (%) 100 100 100 
NYHA class III-IV III-IV III-IV 
BMI (kg/m
2
) 28±3 26±4 28±4 
Haemoglobin (mg/dL) 14±2 14±3 14±2 
Haematocrit (%) 44±4 41±6 42±5 
Total cholesterol (mg/dL) 152±43 162±41 171±46 
Prior hypertension (%) 25 30 39 
Prior smoking (%) 88 84 92 
Diabetes mellitus (%) 63 38 54 
LVEF (%) 24±6 24±4 23±5 
LVESD (mm) 57±8 55±7 56±7 
LVEDD (mm) 65±7 64±7 64±7 
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LEGENDS 
Figure 1. Differentially methylated profile of ASB1 and gene expression in ICM 
patients. A. Methylation pattern of the ASB1 gene in ICM patients showing the 
expansion of the differentially methylated CpG sites between ICM and CNT. B. 
Validation of DNA methylation CpG island by pyrosequencing. C. Gene expression 
analysis of ASB1 gene through RNA-sequencing. CNT, control; ICM, ischaemic 
cardiomyopathy; TSS, transcription start site. *P<0.05.  
Figure 2. Relationships of the differentially methylated CpG site with the invasive-
calculated SV and with eco-Doppler based EF. CNT, control; EF, ejection fraction; 
ICM, ischaemic cardiomyopathy; SV, stroke volume. 


